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T
he 2011 European Respiratory Society
(ERS) Annual Congress was successfully
held in Amsterdam (the Netherlands)
from September 24 to 28. As in recent years, the
Congress was attended by more than 20,000
participants, making this Congress the largest
meeting on a global scale in the field of
respiratory medicine. More than 4,300 abstracts
from research groups around the world were
presented during the 4-day programme, includ-
ing original data and outstanding lectures based
on the most recent literature. This article reports
results pertinent to the most important clinical
problems in the field of respiratory medicine. The
hot topics and the selected abstracts presented at
the Congress from the six scientific groups
(Clinical Problems, Interventional Pulmonology,
Diffuse Parenchymal Lung Disease, Imaging,
General Practice and Primary Care, and
Rehabilitation and Chronic Care) of the Clinical
Assembly are discussed here in the context of
recent literature.
CLINICAL PROBLEMS
The main issues presented at the ERS Congress
were updates on the diagnosis and management
of chronic obstructive pulmonary disease
(COPD), as well as updates exploring conditions
other than COPD.
Diagnosis of COPD and phenotyping
At present, the diagnosis of COPD is typically
considered to be a combination of clinical symp-
toms, exposure to risk factors and the presence of
airflow limitation. The choice of measuring
chronic airflow limitation has recently become a
matter of debate [1]. Most authorities are in favour
of a forced expiratory volume in 1 s (FEV1)/forced
vital capacity (FVC) fixed ratio of ,0.7, whereas
some are in favour of using the lower limit of
normal (LLN) cut-off points [2]. In an elegant
presentation, VESTBO [3] put this discussion into
perspective by presenting unpublished data from
the large Copenhagen City Heart Study that, on
theonehand,provedthefactthatfixedFEV1/FVC
ratio creates false positives but, on the other hand,
clearly pointed out that the difference between
both methods appeared not to be clinically
relevant. More importantly, COPD is not a di-
sease characterised merely by airflow limitation.
Indeed, we are still lacking a gold standard for the
diagnosis of COPD and still rely on clinical
symptoms, but we have to realise that it is a
complex condition with extra-pulmonary effects.
Indeed, several multi-component indices (BODE
(Body mass index, the degree of airflow Ob-
struction, Dyspnoea, and Exercise capacity),
DOSE (Dyspnoea, airflow Obstruction, Smoking
status and Exacerbation frequency) and ADO
(Age, Dyspnoea, airflow Obstruction)) have been
proposed in recent years to better describe the
disease and to establish the prognosis.
Considerable interest during the Congress was
geared towards the issue of heterogeneity of
COPD. The goal of phenotyping the disease is to
identify patient groups with unique prognostic
and therapeutic characteristics. A phenotype
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crelates to ‘‘a single or combination of disease attributes
that describe differences between individuals as they relate
to clinically meaningful outcomes’’ [4]. Different clinical
and physiological manifestations, the presence of systemic
inflammation and comorbidities, acute exacerbations, and
radiological characteristics are potential candidates for the
identification of unique COPD phenotypes. Ongoing initia-
tives, such as the ECLIPSE (Evaluation of COPD to Identify
Predictive Surrogate Endpoints), SPIROMICS (Subpopula-
tions and intermediate outcome measures in COPD) and
COPDGene studies, will shed new light on this topic in
coming years. One possible phenotype recently established
by the ECLIPSE investigators relates to that of the frequent
exacerbations [5]; this seems important because acute exacer-
bations drive the progression of the disease, with increased
morbidity and mortality as a result. In a recent observational
study [6], it was shown that greater lung emphysema and
airway wall thickness derived by quantitative computed
tomography (CT), were associated with an independent
increase in exacerbations, indicating a possible subgroup of
COPD patients who experience frequent exacerbations that
are unknown at present.
Clinical audit in COPD
Results from a European audit sponsored by the ERS,
including 13 European countries and more than 400 hospitals,
were presented in a symposium entitled ‘‘Optimising health-
care for COPD across Europe’’. Records from .16,000 COPD
patients admitted to hospitals for acute exacerbations were
collected to provide data on clinical performance that may be
used to improve service delivery and, ultimately, patient care.
The admitted patients had severe COPD (mean FEV1 41% of
predicted value, 33% still smoking and 24% on long-term
oxygen) but spirometry had been performed in only 60%. More
than 20% had cardiovascular (heart failure, hypertension or
coronary artery disease) and metabolic (diabetes) comorbid-
ities with significant negative impact on outcome. The overall
length of hospital stay was 8 days, and in-hospital and 30-day
mortality were 4.9% and 6.2%, respectively. A higher in-
hospital mortality rate was recorded in those patients having
pulmonary consolidations on chest radiographs (8.1%) or
hypercapnic acidosis (14.5%) on admission. The readmission
rate (35%) varied between countries depending on facilities
such as pulmonary rehabilitation at discharge [7].
COPD treatment
Interestingly, among the several updates during the Congress,
several presentations dealt with innovative therapies. Experts
highlighted that it takes longer for new respiratory drugs to
come to the market as compared with cardiovascular medica-
tions and/or antibiotics. In this regard, patient phenotyping
couldbethewayforwardinprovidingmorerapidaccesstonew
drugs. This was the case for roflumilast, a phosphodisterase-4
inhibitor, which opened a new phenotype-based therapeutic
approach of COPD [8], now approved by both European and
USA authorities. Indeed, robust and reproducible effects of
this anti-inflammatory drug were only seen in patients at risk
for frequent exacerbations and who had clinical symptoms of
chronic bronchitis.
Miscellanea
Advances in the treatment of chronic cough have been
reported in patients with eosinophilic bronchitis, showing a
significant effect after inhalation of budesonide 200 mg b.i.d. for
8 weeks [9], and in individuals with obstructive sleep apnoea-
related cough, showing significant symptom reduction by
using continuous positive airway pressure for 1 month [10].
Updates were also reported in the diagnosis and management
of pneumonia. The level of inflammatory biomarkers (inter-
leukin (IL)-2 and IL-6, tumour necrosis factor-a) on the day of
admission are able to predict the risk of a poor outcome in
community-acquired pneumonia (CAP) [11], whereas the
degree of pulmonary hypertension is likely to predict recurrent
CAP in young patients (aged ,18 yrs) with connective tissue
diseases [12]. A specific composite score (clinical pulmonary
infection score; CPIS) may help with the treatment decision in
patients with hospital-acquired pneumonia during their stay in
hospital [13]. An addition to the expanding list of new
professions (workers in a salami factory) involved in the acute
onset of hypersensitivity pneumonitis (due to Penicillium
antigens) was also reported [14]. Finally, one study tackled
the clinical problems related to end-stage respiratory failure
following interstitial lung diseases. In a retrospective study,
the need for palliative therapies was assessed, which, interest-
ingly, showed that opioids and benzodiazepines were used
with a documented benefit in almost 50% of patients [15].
INTERVENTIONAL PULMONOLOGY
New experiences with endoscopic interventions for patients
with severe lung disease, the use of endobronchial ultrasound
as a leading technology for diagnosis and mediastinal staging
of lung cancer were the main topics discussed at the Congress.
Endoscopic lung volume reduction
Accurate patient selection is the most important and difficult
issue for endoscopic lung volume reduction (ELVR). Therefore,
treatment algorithms are needed to identify those who will
benefit the most. Principally, patients with severe emphysema
should be screened by full lung function testing, including
diffusing capacity of the lung for carbon monoxide, blood gas
analysis and field exercise test (6-min walk test (6MWT)).
Distribution of emphysema and fissure integrity need to
be assessed by high-resolution CT (HRCT) at full inspiration
and by perfusion scan to evaluate the degree of collateral
ventilation [16]. Patients with quite well-recognised functional
characteristics (FEV1 ,45%, total lung capacity .100%,
residual volume .150% of pred, arterial carbon dioxide
tension f60 mmHg, arterial oxygen tension f45 mmHg and
.140 m in the 6MWT) are likely to benefit from ELVR.
Complete lobar occlusion by valve implantation provides an
effective option for patients with heterogeneous upper or
lower lobe predominant emphysema and low collateral
ventilation. However, irreversible and non-blocking endo-
scopic techniques are more effective in patients with upper
lobe predominant emphysema and high collateral ventilation.
Valves
Two different valves are commercially available, endobron-
chial (Zephyr1; Pulmonx Inc., Palo Alto, CA, USA) and
intrabronchial (Spiration1; Olympus Inc., Tokyo, Japan), with
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sion or bilateral partial closure, which lead to redistribution of
ventilation, but avoid atelectasis. A randomised study compar-
ing these modes in 20 patients with severe upper lobe
predominant emphysema has shown a greater benefit in terms
of both FEV1 and 6MWT in patients receiving the unilateral
ELVR with complete lobar occlusion, despite a higher risk of
pneumothorax [17].
Lung volume reduction coils
This consists of implantation of nitinol wire(s) in the airway
(PneumRx Inc., Mountain View, CA, USA) under broncho-
scopy, resulting in parenchymal compression and achievement
of volume reduction (fig. 1). Only one open study with lung
volume reduction coils (10 coils per lobe, placed bilaterally in
12 out of 16 cases) demonstrated significant improvements in
pulmonary function, exercise capacity and quality of life, with
an acceptable safety procedure [18].
Polymeric lung volume reduction
This technique involves administering a foam sealant (Aeris
Therapeutics Inc., Woburn, MS, USA) into the compromised
lung compartments, leading to a local inflammatory reaction
and scar formation (fig. 2), with subsequent volume reduction.
Polymeric lung volume reduction can be offered to patients
with heterogeneous, as well as with homogeneous, disease. In
a multicentre study in 25 patients with upper lobe predomi-
nant emphysema, polymeric lung volume reduction produced
the greatest physiological and clinical effects in Global
Initiative for Chronic Obstructive Lung Disease (GOLD) stage
IV of COPD [19].
Bronchoscopic thermal vapour ablation
This is an alternative method to polymeric lung volume
reduction and consists of delivering heated water vapour
through a vapour generator and a special bronchoscopic
catheter (Uptake Medical, Seattle, WA, USA) to the most
destroyed lung regions, thus inducing a local inflammatory
reaction (fig. 3). A multinational study evaluated the efficacy
of bronchoscopic thermal vapour ablation (vapour dose
42 J?g
-1 (10 cal?g
-1)) in 44 patients with upper lobe predomi-
nant emphysema. Volume reduction (48%) of the treated
lobe, as assessed by HRCT, was reported after 6 months:
FIGURE 1. Delivery of coils into the airways through a catheter. After deployment, the nitinol wire assumes a pre-determined coil shape, while the diseased tissue is
compressed.
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reported after the treatment [20].
Endobronchial ultrasound
Mediastinal nodal sampling has traditionally been performed
using surgical techniques that may result in significant
morbidity and mortality. Endoscopic ultrasound (EBUS) to
guide transbronchial needle aspiration (TBNA) of mediastinal
lymph nodes has been developed as a safer, less invasive and
more cost-effective procedure [21, 22].
Potentially, this technique may yield cytological specimens
inadequate of providing a firm diagnosis. Indeed, immuno-
histochemistry and mutational analysis from sufficiently large
tissue samples are extremely important in the process of
a) b)
FIGURE 2. Effect of the application of polymeric lung volume reduction for endodcopic lung volume reduction. Scar tissue is visible on coronal computed tomography
images in the right upper lobe after intervention (b) 6–8 weeks after treatment.
a) b)
FIGURE 3. a) Pre- and b) post-changes (3 months) after bronchoscopic thermal vapour ablation of the right upper lobe. Tissue volume changes can be seen on coronal
computed tomography images in the panels. Each lobe is represented by coloured overlays.
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tion of tumours express mutations of cell surface receptors (i.e.
epidermal growth factor receptor) at which specific molecules,
such as gefitinib and erlotinib, may direct their anti-prolif-
erative effect. In past years, tests for mutations could only be
performed on block tumours post-resection. However, more
recent advances in molecular biology led to the ability to also
test small biopsy specimens for such mutations by PCR
analysis, fluorescence in situ hybridisation and immunohisto-
chemistry. As shown during the ERS Congress, EBUS-TBNA
offers the opportunity to obtain adequate samples through a
nonsurgical biopsy technique, allowing combined pathological
and molecular analysis of metastatic lymph nodes to be
performed [23–26].
DIFFUSE PARENCHYMAL LUNG DISEASES
Clinical characterisation and new frontiers in the therapy of
idiopathic pulmonary fibrosis (IPF), as well as rare diseases of
the lung appearing with cystic lesions were significant topics
reported during the ERS Congress.
Advances in the definition of IPF
Different patterns of interstitial lung disease frequently (up
to 4%) occur among smokers screened for lung cancer [27],
showing that both conditions may share some pathogenetic
mechanisms [28]. IPF is the most common of the idiopathic
interstitial pneumonias and is associated with tobacco smoking.
A recent consensus providing simplified criteria for the
diagnosis of IPF emphasised the importance of multidisciplin-
ary discussion between clinicians, radiologists and patholo-
gists in improving diagnostic confidence [29]. The pattern
of usual interstitial pneumonia (UIP) (subpleural reticular
abnormality and honeycombing, with or without traction
bronchiectasis, in the lung basal regions) on chest HRCT in
the absence of other known causes for UIP is typical, thus
emphasising the diagnostic role of imaging. However, exten-
sive ground-glass opacity, profuse micronodules, cysts, diffuse
air-trapping or alveolar consolidation in the upper/mid lobes
are more likely to be ‘‘inconsistent with UIP’’. The histopatho-
logical lesions that characterise the UIP pattern are patchy
areas of fibrosis (excessive collagen deposition), honeycomb
changes, the mandatory presence of fibroblastic foci and, at the
same time, the absence of any feature suggesting an alternative
diagnosis [30]. Thus, combinations of HRCT and results of the
lung biopsy, when available, may result in four categories of
diagnostic certainty in IPF (IPF, probable IPF, possible IPF and
not IPF).
Nonetheless, the clinical profile and patterns defined by
imaging and pathology are not yet completely defined. First,
the inter-observer agreement to recognise honeycombing
change decreases when pulmonary fibrosis and emphysema
coexist [30]. Secondly, immunohistochemistry other than the
usual haematoxylin-eosin stain could be more useful for an
objective morphological definition [31]. Thirdly, IPF shows
clinical and radiological heterogeneity, such as that docu-
mented in the asymmetrical disease, associated with a
higher rate of gastro-oesophageal reflux and of episodes of
acute exacerbations [32]. Fourthly, serum biomarkers could
help both diagnosis and prognosis in the near future [33].
Finally, easily available clinical data, such as age .65 yrs,
modest amounts of fibrosis on HRCT scan [34] and family
history of pulmonary fibrosis [35], may also help to suspect a
diagnosis of IPF, which is not the case for other parameters
(sex, smoking habit, lung function, oxygen abnormalities and
distance walked in the 6MWT). As a matter of fact, a ‘‘benign’’
clinical course is reported in patients with a diagnosis of
idiopathic nonspecific interstitial pneumonia [36].
Therapeutic options in IPF
Studies evaluating the efficacy of nonsteroid agents in large
cohorts of patients with mild or moderate IPF have created
new expectations for the therapy of this disease [37], and good
news is expected from ongoing placebo-controlled trials using
new and more specific molecules.
Recent clinical trials supported the role of pirfenidone to limit
the decline of lung function and to improve time to disease
progression in these patients, with an acceptable tolerability
and safety profile [38]. More recently, the efficacy and safety of
a potent intracellular inhibitor of tyrosine kinases (BIBF 1120)
was assessed in a 12-month, phase-II trial, also including
patients with mild-to-moderate IPF. At a dose of 150 mg b.i.d.,
the drug showed a positive trend toward a reduction in the
decline of lung volumes, with fewer acute exacerbations and
preserved quality of life [39].
Cystic lung diseases
The spectrum of diseases appearing with cystic changes in the
lungs is widening [40], and may mimic those of lymphangio-
leiomyomatosis. Among these, severe bronchiolitis has been
reported as a presenting feature of the primary Sjo ¨gren’s
syndrome [41], while genetic mutations [42, 43] and other
congenital disorders [44] have been recognised as a cause of
cysts in the lung with familial spontaneous pneumothorax, and
rare lung or extra-pulmonary tumours.
Finally, chronic damage to the small airways (such as during
exposure to inhalants or in the case of neuro-endocrine
bronchiolar hyperplasia) [45], and non-amyloid immunoglobu-
lin deposition disease may rarely determine cystic lung lesions.
CHEST IMAGING
To date, imaging is used for the morphological assessment of
lung parenchymal diseases. Although pulmonary function
evaluation is considered more important for staging and
follow-up than imaging in most lung diseases, emerging
imaging technologies and strategies might get this target more
and more into reach.
Functional imaging
CT is the most established technique for visualisation of the
lung parenchyma. Image acquisition can be triggered to
respiration (four-dimensional (4D)-CT) so that the ventilated
lung volumes during free breathing can be assessed [46];
furthermore, the regional motion of the lung parenchyma can
be traced, thus, generating motion maps. A high agreement
(r50.93) for ventilation defects was found in comparison with
ventilation single photon emission CT imaging [47]. As a
drawback of the 4D-CT technique, a high radiation dose has to
be administered, and perfusion cannot be assessed at the same
time.
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(MRI) techniques have been deployed. A novel method for
generating ventilation/perfusion (V9/Q9) maps was presented
at the 2011 ERS Congress. This was based on oxygen-enhanced
MRI performing a model fitting calculation of the pulmonary
perfusion [48]. In contrast with healthy volunteers, V9/Q9 was
found to be increasingly heterogeneous in patients with
moderate-to-severe COPD, with no difference between the
subgroups with or without emphysema [49]. Therefore, these
techniques allow for assessment of the functional impact of
typical morphological changes with a high-spatial resolution.
Another important aspect of lung pathophysiology is the
regional compliance of the lung parenchyma [50]. Noninvasive
assessment of this parameter is difficult but could be important
for validation of new treatment options in diseases such
as pulmonary fibrosis or COPD. A recently proposed MRI
method facilitating dynamic imaging of the lung parenchyma
has shown a significant increase of lung compliance in COPD
patients compared with healthy volunteers [51].
Image-based characterisation of COPD
Since CT is the standard for imaging the lung parenchyma, it
may be used in longitudinal studies to assess changes in
parenchymal density and lung mass or treatment response.
Based on data from the Danish Lung Cancer Screening Trial,
2,052 people were examined over 5 yrs with annual CT scans
[52]. The annual decline in volume density of male ex-smokers
(reference group) was -0.38 g?L
-1?yr
-1, with ,70% increased
rates of decline in females, current smokers and in subjects
with airflow obstruction. Data suggest these characteristics are
factors influencing the change in lung density that needs to be
taken into account for evaluation in prospective studies.
Phenotyping of emphysematous lung changes is also a new
approach to characterise patient groups and to predict their
outcome. The lobar predominance of emphysema was assessed
at baseline and after 2.9 yrs in a cohort of 587 patients [53];
participants with upper lobe emphysema had an additional
risk (+71%) of decreased FEV1/FVC at follow-up when
compared to patients with lower lobe emphysema (p50.001),
independent of the total extent of the disease. Therefore, it
might be argued that upper lobe predominant disease is a
specific phenotype of emphysema.
With specific regard to COPD, some patients show more
enhanced changes in the lung parenchyma while others do
show more airway disease. The tracheo-bronchial collapsibility
has been assessed using inspiratory–expiratory CT in relation-
ship to the specific phenotype in 36 patients [54]; this index
was significantly higher in patients with chronic bronchitis
(p50.02), suggesting that a similar inflammatory process could
involve both trachea and the bronchial tree.
GENERAL PRACTICE AND PRIMARY CARE
In the field of general practice, several sessions at the ERS
Congress and during the Primary Care Day reported on recent
developments aimed at establishing an early, but valid,
diagnosis; thus, improving the quality of patient care and
disease management, and keeping on track with promising
advances in tele-health and integrated care.
Early diagnosis and quality of assessment
In a pilot study, HAROON et al. [55] investigated the yield of a
targeted approach (questionnaire) for case finding versus an
opportunistic approach (visit to a general practitioner (GP)).
Patients with symptoms were invited to attend spirometry and
those showing airway obstruction were referred to the primary
care level. Only 1.2% in the targeted arm and 1.5% in the
opportunistic arm were identified with airway obstruction.
In a Danish study [56], the authors assessed the effectiveness of
a two-stage screening programme by posting a questionnaire
to subjects aged o65 yrs, followed by spirometry in (former)
smokers or when experiencing morning cough with sputum
and/or dyspnoea. A total of 1,352 (19%) subjects performed
spirometry. Of these, 44% were diagnosed to have mild (42%),
moderate (43%) or severe-to-very severe (14%) COPD.
Non-routine healthcare utilisation in the 2–10 yrs prior to
COPD diagnosis was analysed by PRICE et al. [57] in a large
retrospective observational study. In the 2 yrs prior to
diagnosis, 56% of patients were consulted for respiratory
complaints (26% for lower respiratory tract infections) and
most of them (34%) received multiple prescriptions for oral
steroids and/or antibiotics. The same patients recorded more
hospitalisations over the 4 yrs prior to diagnosis.
To assess adherence to GOLD guidelines and appropriateness
of prescribing, BOOTH et al. [58] extracted data on COPD
management in 65 general practices. Spirometry was recorded
for 2,941 (61%) individuals, with confirmed diagnosis of COPD
in 2,163. Up to 62% were inappropriately treated according to
GOLD, with over-prescription of inhaled corticosteroids in
GOLD stage I/II (55%), or in stage III/IV with no history of
severe exacerbations (56%) being the most common deviation.
The quality of health services was recorded at primary care
level in 200 Indian patients with asthma [59]. Around 15% of
the subjects were being treated by unqualified practitioners
and ,50% by GPs. Among those treated by unqualified
practitioners, 64% were being inappropriately prescribed
bronchodilators and oral corticosteroids. In the same field of
asthma management, TERMEER et al. [60] explored the con-
sequences of using exhaled nitric oxide fraction (FeNO)a sa n
adjunct to symptoms and spirometry for assessing disease
control in Dutch primary care. In almost half the population,
FeNO may result in fine-tuning of the categorisation of asthma
control.
Finally, MENZIES and WIGGINS [61] investigated the use of pulse
oximeters by GPs in the UK, and found that over a third of
them did not yet own the device, despite current guideline
indications for assessment and management and the fact that
most of the users (89%) did consider this tool very useful.
Managing comorbidities
The associations between comorbidity and mortality were
investigated in 552 Swedish COPD patients [62]. Over a 5-yr
period, 22% of the patients died; adjusted mortality rates
were significantly higher in patients with cardiac diseases
and hypertension and who were underweight. Interestingly,
GIL et al. [63] investigated the risk of treating patients with
both heart failure and mild-to-moderate COPD with b-
blockers. In all 43 patients with an average ejection fraction
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respiratory failure over the following year. The specific pro-
blem of coexisting left heart failure in COPD has been
evaluated in 101 patients in a cohort of ,800 subjects in the
UK [64]. Although the coexistence of heart failure and COPD
was associated with increased hospitalisations, 2-yr survival
was similar in these patients (89%) when compared with heart
failure alone (93%).
Telemedicine and integrated care
In recent years, the interest in telemonitoring services for
COPD patients has grown considerably. Patients may use
teledata to determine their state of health and to validate their
decision to contact healthcare professionals earlier in order to
prevent admissions. Conversely, professionals may emphasise
the role of telemetry in encouraging compliance and facilitat-
ing patient self-management. FAIRBROTHER et al. [65] explored
the views of patients and professionals participating in a trial
on home telemonitoring, and showed that both sides perceived
that this service reduced the risk of re-admission.
BOONSAWAT [66] reported a large-scale (900 hospitals serving
99,535 asthmatics) implementation of asthma guidelines
through the Easy Asthma Clinic in Thailand. Peak flow
measurement performance improved from 1% to 98%, inhaled
corticosteroid use increased from 11% to 79% throughout the
visits, and asthma control was fully (23%) or partially (46%)
achieved. In another implementation study in the Netherlands,
the authors hypothesised that a secured web-based telespiro-
metry service would reduce referrals and improve triage
among respiratory patients [67]. 75% of the teleconsultations
originally intended for referral were prevented, whereas 22%
of the teleconsultations for advice were referred for further
investigation.
In the same country, PRINSEN et al. [68] described the effect of
clinical advice (from pulmonologist to GP) from an integrated
care system on health status in COPD patients. Over time,
improvement or deterioration of health status was measured in
27% and 29% of patients, respectively. Although this care
model demonstrated statistically significant benefit to COPD
health status, the clinical implications remain unclear.
REHABILITATION AND CHRONIC CARE
Multiple abstracts were presented at the 2011 ERS Congress
covering the area of rehabilitation and chronic care. Five young
scientists were awarded a sponsored grant for Best Abstracts in
Rehabilitation and Chronic Care.
Impact of comorbidities
Systemic inflammation may initiate or worsen comorbid
diseases (ischaemic heart disease, heart failure, osteoporosis,
depression and diabetes) in patients with COPD; the spill-over
of inflammatory mediators into the circulation of these patients
has been suggested as a possible mechanism [69]. Recently,
multiple markers of systemic inflammation have been asso-
ciated with an increased fat mass in these patients [70, 71].
VAN DEN BORST et al. [72] hypothesised that visceral adipose
tissue is related to systemic inflammation in subjects with
clinically stable obstructive lung disease (defined as FEV1/FVC
below LLN). Obstructive lung disease subjects had greater
visceral adiposity and elevated levels of IL-6, plasminogen
activator inhibitor-1 and adiponectin compared with matched
controls, while whole-body and appendicular/trunk fat mass
were comparable. Therefore, higher visceral adipose tissue may
reflect a disturbed metabolic function contributing to systemic
manifestations. Whether variation in visceral adipose tissue
distribution contributes to the prevalence of obesity-related
diseases and whether comprehensive rehabilitation, including
aerobic exercise training and nutritional counselling, may
benefit patients with airway obstruction still remains unknown.
Nevertheless, aerobic exercise is central for exercise pro-
grammes aimed at reducing visceral adipose tissue, and aerobic
exercise below current recommendations for obesity manage-
ment may be sufficient for beneficial visceral adipose tissue
modification [73].
Exercise modalities and physiological response
Exercise training is recognised as the cornerstone of compre-
hensive pulmonary rehabilitation programmes in patients with
chronic respiratory disease [74]. High-intensity interval train-
ing can be considered as an alternative to continuous training
in patients with varying degrees of COPD severity to improve
exercise performance and health status [75, 76]. GLOECKL et al.
[77] compared the feasibility and effects of high-intensity
interval (30-s exercise bouts at 100% of baseline peak load and
30-s rest for 10–30 min) with continuous (60% of baseline load
for 12–36 min) volume-equivalent training in 60 in-patients
with COPD before lung transplantation during a 3-week
programme. While exercise performance improved signifi-
cantly to the same extent in both groups, as demonstrated in
previous studies in the moderate stage of the disease [78],
dyspnoea scores and the number of unintended stops were
higher during the continuous modality, showing that high-
intensity interval training seems better tolerated by the most
severe patients.
Local lower-limb muscle training, like high-intensity resistance
training or transcutaneous neuromuscular electrical stimula-
tion, has also been shown to be beneficial [79, 80]. In a
randomised, double-blind, placebo-controlled trial, HOUCHEN
et al. [81] studied the enhancing effects of protein supplemen-
tation during an 8-week resistance training programme (five
times 30 bilateral knee extensions three times a week) in 59
patients with moderate-to-severe COPD; lower-limb muscle
function, thigh lean mass and peak exercise performance
improved compared with baseline similarly in patients with or
without supplementation. This further confirms that resistance
training is feasible and effective in COPD patients [82] but
the addition of a protein supplement did not augment the
functional benefits.
Whole-body exercise testing and high-intensity exercise train-
ing may result in dynamic hyperinflation and large intra-
thoracic pressure swings [83], which may further compromise
the impaired cardiac output in the COPD population [84].
VASILOPOULU et al. [85] studied the effect of disease severity on
haemodynamic responses during a 6MWT and cycling at a
constant 75% of the peak power output in 60 COPD patients in
GOLD stages I to IV. Cardiac output kinetics were similar
between both exercise tests, but a GOLD stage-dependent
increase was observed for on-transient and off-transient time
constants (i.e. slowest) in GOLD stage IV patients, reflecting a
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advanced disease and/or deconditioning.
End-of-life in chronic diseases
JANSSEN et al. [86] investigated 1-yr stability of preferences
regarding cardiopulmonary resuscitation and mechanical
ventilation in 265 patients with advanced COPD, or chronic
heart or renal failure, and identified that preferences changed
at least once in 38% of the patients during the follow-up. A
change from preferring life-sustaining treatment to refusing
such treatment was predicted by a decrease in health status
and mobility, and by an increase in symptoms of anxiety and
depression; a change from refusing to preferring life-sustaining
treatment was also predicted by a decrease in health status, as
well as by the loss of a spouse [87]. These data suggest that
regular re-evaluation of advance care planning is necessary in
patients with chronic disease.
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